These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23071034)

  • 1. Setting the stage for cancer startups.
    Cancer Discov; 2012 Oct; 2(10):OF11. PubMed ID: 23071034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investing in oncology biotech stocks.
    Feuerstein A
    Clin Adv Hematol Oncol; 2007 Nov; 5(11):879-80. PubMed ID: 18185485
    [No Abstract]   [Full Text] [Related]  

  • 3. Early-stage returns?
    Booth BL
    Nat Biotechnol; 2006 Nov; 24(11):1335-40. PubMed ID: 17093473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sense and antisense for investors.
    Jacobs T
    Nat Biotechnol; 2002 Jun; 20(6):543. PubMed ID: 12042846
    [No Abstract]   [Full Text] [Related]  

  • 5. How Genentech got it.
    Stipp D
    Fortune; 2003 Jun; 147(11):81-2, 84, 86 passim. PubMed ID: 12800575
    [No Abstract]   [Full Text] [Related]  

  • 6. Rising costs hold up drug discovery.
    Miller HI
    Nature; 1998 Oct; 395(6705):835. PubMed ID: 9804407
    [No Abstract]   [Full Text] [Related]  

  • 7. Discontinued drugs in 2010: oncology drugs.
    Williams R
    Expert Opin Investig Drugs; 2011 Nov; 20(11):1479-96. PubMed ID: 21955127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new anti-cancer drug in the market: Good news for investors or for patients?
    Apolone G; Tafuri G; Trotta F; Garattini S
    Eur J Cancer; 2008 Sep; 44(13):1786-8. PubMed ID: 18672359
    [No Abstract]   [Full Text] [Related]  

  • 9. Where have all the investors gone?: the case for consolidation.
    Esposito RS; Ostro MJ
    Nat Biotechnol; 1998 May; 16 Suppl():63. PubMed ID: 9591277
    [No Abstract]   [Full Text] [Related]  

  • 10. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 11. No pain, no gain?
    Jacobs T
    Nat Biotechnol; 2005 Aug; 23(8):934. PubMed ID: 16082357
    [No Abstract]   [Full Text] [Related]  

  • 12. Pfizer's home remedy.
    Abkowitz A
    Fortune; 2009 Aug; 160(4):82-4, 86. PubMed ID: 19728588
    [No Abstract]   [Full Text] [Related]  

  • 13. Gold in the ivory tower: equity rewards of outlicensing.
    Edwards M; Murray F; Yu R
    Nat Biotechnol; 2006 May; 24(5):509-15. PubMed ID: 16680129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer pathways' target not validated by clinical results.
    Ratner M
    Nat Biotechnol; 1999 Mar; 17(3):220. PubMed ID: 10096279
    [No Abstract]   [Full Text] [Related]  

  • 15. Industry, clinical trials, and the cost of cancer drugs: an investor's perspective.
    Fiorino T
    J Clin Oncol; 2007 Jul; 25(19):e21-3. PubMed ID: 17602065
    [No Abstract]   [Full Text] [Related]  

  • 16. Are the large pharmaceutical and biotechnology companies driving the discovery, research and development of targeted cancer therapies?
    Gallant GJ
    Future Med Chem; 2012 Jan; 4(1):13-7. PubMed ID: 22168161
    [No Abstract]   [Full Text] [Related]  

  • 17. Investors remain wary after first quarter downturn.
    Fletcher L
    Nat Biotechnol; 2002 May; 20(5):413-4. PubMed ID: 11981536
    [No Abstract]   [Full Text] [Related]  

  • 18. Sugen's strategy: a signal for P&U purchase.
    Glaser V
    Nat Biotechnol; 1999 Aug; 17(8):745-6. PubMed ID: 10429230
    [No Abstract]   [Full Text] [Related]  

  • 19. Investors likely to venture back as crisis subsides.
    Glick JL
    Nature; 2009 Aug; 460(7259):1079. PubMed ID: 19713912
    [No Abstract]   [Full Text] [Related]  

  • 20. Organizing for innovation: towards successful translational research.
    West W; Nightingale P
    Trends Biotechnol; 2009 Oct; 27(10):558-61. PubMed ID: 19683820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.